Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Ontruzant 150mg pdr for concentrate for inf vials
0801050ADBDAAAA
|
Ontruzant | Trastuzumab | Malignant Disease and Immunosuppression | No data available |
|
Opazimes chewable tablets
0104020N0BFAAAG
|
Opazimes | Opium and morphine | Gastro-Intestinal System | No data available |
|
Opdivo 100mg/10ml concentrate for inf vials
0802040ATBBABAB
|
Opdivo (old) | Nivolumab (old) | Malignant Disease and Immunosuppression | No data available |
|
Opdivo 240mg/24ml concentrate for inf vials
0802040ATBBACAC
|
Opdivo (old) | Nivolumab (old) | Malignant Disease and Immunosuppression | No data available |
|
Opdivo 40mg/4ml concentrate for solution for infusion vials
0802040ATBBAAAA
|
Opdivo (old) | Nivolumab (old) | Malignant Disease and Immunosuppression | No data available |
|
Open wove bandage type 1 BP 1988 10cm x 5m
20020200504
|
Open wove bandage type 1 BP 1988 10cm x 5m | Arm Sling/Bandages | Dressings | No data available |
|
Opiodur 100micrograms/hour transdermal patches (Pfizer)
0407020A0BRADAH
|
Opiodur | Fentanyl | Central Nervous System | No data available |
|
Opiodur 100micrograms/hour transdermal patches (RX Farma)
0407020A0BRAJAH
|
Opiodur | Fentanyl | Central Nervous System | No data available |
|
Opiodur 12micrograms/hour transdermal patches (Pfizer)
0407020A0BRAAAU
|
Opiodur | Fentanyl | Central Nervous System | No data available |
|
Opiodur 25micrograms/hour transdermal patches (Pfizer)
0407020A0BRABAE
|
Opiodur | Fentanyl | Central Nervous System | No data available |
|
Opiodur 50micrograms/hour transdermal patches (Pfizer)
0407020A0BRAEAF
|
Opiodur | Fentanyl | Central Nervous System | No data available |
|
Opiodur 75micrograms/hour transdermal patches (RX Farma)
0407020A0BRAIAG
|
Opiodur | Fentanyl | Central Nervous System | No data available |
|
Opizone 50mg tablets
0410030E0BCAAAA
|
Opizone | Naltrexone hydrochloride | Central Nervous System | No data available |
|
Oprymea 0.18mg tablets
0409010W0BDABAB
|
Oprymea | Pramipexole | Central Nervous System | No data available |
|
Oprymea 0.35mg tablets
0409010W0BDACAD
|
Oprymea | Pramipexole | Central Nervous System | No data available |
|
Oprymea 0.52mg modified-release tablets
0409010W0BDAFAF
|
Oprymea | Pramipexole | Central Nervous System | No data available |
|
Oprymea 0.7mg tablets
0409010W0BDADAA
|
Oprymea | Pramipexole | Central Nervous System | No data available |
|
Oprymea 2.62mg modified-release tablets
0409010W0BDAJAK
|
Oprymea | Pramipexole | Central Nervous System | No data available |
|
Oprymea 3.15mg modified-release tablets
0409010W0BDAKAI
|
Oprymea | Pramipexole | Central Nervous System | No data available |
|
OpSite Plus dressing 5cm x 5cm
20030100250
|
OpSite Plus dressing 5cm x 5cm | Wound Management & Other Dressings | Dressings | No data available |
|
Opsumit 10mg tablets
0205010AABBAAAA
|
Opsumit | Macitentan | Cardiovascular System | No data available |
|
Optaflu vacc inj 0.5ml pre-filled syringes
1404000H0BPAAAF
|
Optaflu | Influenza | Immunological Products and Vaccines | No data available |
|
Optibac Babies and Children 1.5g sachets
0913531C0BDAAAC
|
Optibac Babies and Children powder delisted probiotic | Powder delisted probiotic (0913531) | Nutrition and Blood | No data available |
|
Optibac Baby 0-3 years oral drops
0913531A0BFAAAG
|
Optibac liquid OTC probiotic | Liquid OTC probiotic (0913531) | Nutrition and Blood | No data available |
|
Optibac Bifido & Fibre 6g sachets
0913531C0BEAAAD
|
Optibac Bifido & Fibre 6g sachets delisted probiotic | Powder delisted probiotic (0913531) | Nutrition and Blood | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.